7 Hills Pharma receives a $3 million SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop the first vaccine for Chagas disease. This innovative vaccine combination with 7HP349 aims to protect millions from the Trypanosoma cruzi parasite and prevent severe outcomes of the disease.

7 Hills Pharma announces the successful completion of a Phase I clinical trial for 7HP349, an oral immunostimulant that enhances immuno-oncology drugs, COVID-19, and influenza vaccines. The study demonstrated excellent safety, tolerability, and pharmacokinetics, paving the way for Phase II clinical trials in solid tumors and vaccination for immunocompromised populations.

Researchers from the Texas Heart Institute, UTMB, and 7 Hills Pharma have pioneered a groundbreaking study on the use of 7HP349, an oral integrin activator, as a vaccine adjuvant. This research, published in Nature Partner Journal Vaccines, shows how 7HP349 enhances immune responses, with promising applications for Chagas disease and COVID-19 vaccines, particularly in immunocompromised individuals.

7 Hills Pharma appoints Michael S. Perry, CEO of AVITA Medical, as its first Chairman of the Board of Managers. The company is advancing small molecule integrin activators, including 7HP349, to enhance immuno-oncology drugs and vaccines for COVID-19, influenza, and cancer treatments.

7 Hills Pharma is developing 7HP349, a novel immune activator to enhance the effectiveness of COVID-19 and influenza vaccines as well as cancer immunotherapies. This proprietary compound activates integrins, improving cell adhesion and immune responses, and aims to address age-related immune deficiencies, ultimately improving treatment outcomes for vulnerable populations.

7 Hills Pharma announces the first healthy volunteers dosed in its Phase 1 trial of 7HP349, an immunostimulant aimed to enhance immuno-oncology drugs and COVID-19 & influenza vaccines, improving immune responses and increasing effectiveness in older adults.

7 Hills Pharma secures broad USPTO patent protection for its integrin activators, positioning the company as a key partner for immuno-oncology and COVID-19 vaccine developers. FDA-approved IND trials set to begin soon.

7 Hills Pharma announces positive preclinical data on 7HP349, an oral immunostimulant that enhances COVID-19 vaccine effectiveness by boosting IgG antibody responses and accelerating immune protection. Learn how this integrin activator could improve vaccine efficacy, particularly for older adults.

Discover how 7 Hills Pharma’s integrin activators enhance immunotherapies by boosting cell adhesion, improving COVID-19 vaccines, checkpoint inhibitors, and cancer treatments. Learn more from BIO Digital 2020.

7 Hills Pharma’s integrin platform technology enhances immunotherapies, boosting COVID-19 vaccine efficacy and checkpoint inhibitors by improving cell adhesion for stronger immune responses. Learn more from BIO Digital 2020.

7 Hills Pharma launches a COVID-19 vaccine program targeting at-risk elderly, leveraging integrin activator technology to enhance immune responses and improve vaccine effectiveness. Learn more about this breakthrough approach.